Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly anticounterfeit measures

Executive Summary

Lilly is exploring use of radio frequency identification on its products in pilot programs as part of multi-pronged anticounterfeit strategy. Other measures include Canadian supply allocation program, direct-buying requirement for wholesalers, and establishment of a global product protection division. The company's Feb. 5 press release describing the measures will be submitted to House Energy & Commerce Committee as requested under its counterfeit drug investigation (1"The Pink Sheet" Jan. 19, 2004, p. 13). Lilly's Zyprexa, Cialis and insulin products have been the subject of counterfeit concerns...

You may also be interested in...



Manufacturers’ Anticounterfeiting Plans Sought In House Cmte. Investigation

The House Energy & Commerce Committee is asking five brand-name drug manufacturers to submit information on their efforts to prevent counterfeiting

More IVD Mergers: Agilent Buys Resolution, Hologic Acquires Diagenode

Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.

Merck & Co. Will Manufacture J&J Vaccine, Other COVID-19 Medicines Under BARDA Deal

Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel